Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Trading Up 3.9 %

NERV stock opened at $1.61 on Thursday. The firm has a 50 day moving average of $1.89 and a 200-day moving average of $2.21. The firm has a market capitalization of $11.26 million, a P/E ratio of -3.66 and a beta of 0.10. Minerva Neurosciences has a 12 month low of $1.42 and a 12 month high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.49. Sell-side analysts predict that Minerva Neurosciences will post -0.3 EPS for the current year.

Institutional Trading of Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Northern Trust Corp increased its position in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,878 shares of the biopharmaceutical company’s stock after purchasing an additional 13,829 shares during the period. Northern Trust Corp owned 0.53% of Minerva Neurosciences worth $82,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.